FDA Approves Abbot’s MitraClip For Patients At Prohibitive Surgical Risk

The FDA today approved Abbott’s catheter-based MitraClip device for patients with significant symptomatic degenerative MR who are at prohibitive risk for mitral valve surgery. The company said it would launch the device immediately in the United States. The device is the first percutaneous nonsurgical therapy approved for the treatment of mitral valve disease.

Click here to read the full post on Forbes.

 

Mitraclip

 

Leave a Reply

%d bloggers like this: